Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC	MIBC	Recruiting	Phase 3	2026-07-09		NCT07693959

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Tongji Hospital	276
Zhiquan Hu	2

22 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center	Shenzhen	China	2
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	1
Fujian Medical University Union Hospital	Fuzhou	China	107
Huanggang Central Hospital	Huanggang	China	4
Huangshi Central Hospital	Huangshi	China	5
Hubei Cancer Hospital	Wuhan	China	95
Jiangxi Provincial People's Hospital	Nanchang	China	19
Jingmen Central Hospital	Jingmen	China	2
Jingzhou Central Hospital	Jingzhou	China	14
Jingzhou First People's Hospital	Jingzhou	China	6
Renmin Hospital of Wuhan University	Wuhan	China	42
Shandong Cancer Hospital and Institute	Jinan	China	10
Taihe Hospital	Shiyan	China	6
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture	Enshi	China	1
The Central Hospital of Wuhan	Wuhan	China	9
The First affiliated Hospital of Anhui Medical University	Hefei	China	56
The First Affiliated hospital of Xiamen University	Xiamen	China	69
Wuhan No.1 Hospital	Wuhan	China	2
Xiangyang Central Hospital	Xiangyang	China	17
Yichang Central People's Hospital	Yichang	China	17
Zhongnan Hospital of Wuhan University	Wuhan	China	65
Zhujiang Hospital of Southern Medical University	Guangzhou	China	33

Clinical trials